Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06365853 · ClinicalTrials.gov registry record · Phase 2
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
A Phase 2 study of Recurrent Ovarian Cancer and Folate Receptor-Alpha Positive, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06365853 is a Phase 2 study of Recurrent Ovarian Cancer and Folate Receptor-Alpha Positive that is actively recruiting participants, run by AbbVie. The registered enrollment target is 100 participants, below the 174-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06365853, a Phase 2 study of Recurrent Ovarian Cancer and Folate Receptor-Alpha Positive, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
Conditions Studied
Interventions
- DRUG Mirvetuximab Soravtansine
- DRUG Lubricating Eye Drops
- DRUG Prednisolone acetate ophthalmic suspension 1% eye drops
- DRUG Brimonidine tartrate ophthalmic solution eye drops
Study Locations (20)
Oost-Vlaanderen
- OLV Ziekenhuis Aalst /ID# 269311 - Aalst
- AZ Sint-Lucas /ID# 269307 - Ghent
- UZ Gent /ID# 269309 - Ghent
New York
- New York Oncology Hematology - Albany Cancer Center /ID# 269345 - Albany
- Women'S Cancer Care Associates /ID# 269980 - Albany
Texas
- UT Southwestern Medical Center /ID# 269341 - Dallas
- Memorial Hermann Southeast Hospital /ID# 269347 - Houston
New South Wales
- Blacktown Hospital /ID# 269305 - Blacktown
- Newcastle Private Hosptial /ID# 269306 - Lambton Heights
California
- University of California Los Angeles /ID# 269339 - Los Angeles
Kentucky
- Norton Cancer Institute - St. Matthews /ID# 269070 - Louisville
Maryland
- Holy Cross Hospital - Silver Spring /ID# 269344 - Silver Spring
Missouri
- Mercy David C. Pratt Cancer Center /ID# 269350 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06365853
The ClinicalTrials.gov registry entry for NCT06365853 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (43% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which Mirvetuximab Soravtansine is the first listed.
NCT06365853 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Oost-Vlaanderen, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06365853 about?
NCT06365853 is a clinical study titled "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression". The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic ev...
What is the current status of trial NCT06365853?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-07-29. Estimated completion is 2027-06.
What conditions does trial NCT06365853 study?
This clinical trial studies the following conditions: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive.
What interventions are being tested in trial NCT06365853?
The interventions under investigation include: Mirvetuximab Soravtansine (DRUG), Lubricating Eye Drops (DRUG), Prednisolone acetate ophthalmic suspension 1% eye drops (DRUG), Brimonidine tartrate ophthalmic solution eye drops (DRUG).
Who is sponsoring clinical trial NCT06365853?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06365853 being conducted?
This trial has 20 study locations across California, Kentucky, Maryland, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
COMPLETED · Phase 2
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
-
Combination Therapy for Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.